The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Intensive Diabetes Therapy and Glomerular Filtration Rate in Type 1 Diabetes
Open accessAbstract
BACKGROUND: An impaired glomerular filtration rate (GFR) leads to end-stage renal disease and increases the risks of cardiovascular disease and death. Persons with type 1 diabetes are at high risk for kidney disease, but there are no interventions that have been proved to prevent impairment of the GFR in this population. METHODS: In the Diabetes Control and Complications Trial (DCCT), 1441 persons with type 1 diabetes were randomly assigned to 6.5 years of intensive diabetes therapy aimed at achieving near-normal glucose concentrations or to conventional diabetes therapy aimed at preventing hyperglycemic symptoms. Subsequently, 1375 participants were followed in the observational Epidemiology of Diabetes Interventions and Complications (EDIC) study. Serum creatinine levels were measured annually throughout the course of the two studies. The GFR was estimated with the use of the Chronic Kidney Disease Epidemiology Collaboration formula. We analyzed data from the two studies to determine the long-term effects of intensive diabetes therapy on the risk of impairment of the GFR, which was defined as an incident estimated GFR of less than 60 ml per minute per 1.73 m(2) of body-surface area at two consecutive study visits. RESULTS: Over a median follow-up period of 22 years in the combined studies, impairment of the GFR developed in 24 participants assigned to intensive therapy and in 46 assigned to conventional therapy (risk reduction with intensive therapy, 50%; 95% confidence interval, 18 to 69; P=0.006). Among these participants, end-stage renal disease developed in 8 participants in the intensive-therapy group and in 16 in the conventional-therapy group. As compared with conventional therapy, intensive therapy was associated with a reduction in the mean estimated GFR of 1.7 ml per minute per 1.73 m(2) during the DCCT study but during the EDIC study was associated with a slower rate of reduction in the GFR and an increase in the mean estimated GFR of 2.5 ml per minute per 1.73 m(2) (P<0.001 for both comparisons). The beneficial effect of intensive therapy on the risk of an impaired GFR was fully attenuated after adjustment for glycated hemoglobin levels or albumin excretion rates. CONCLUSIONS: The long-term risk of an impaired GFR was significantly lower among persons treated early in the course of type 1 diabetes with intensive diabetes therapy than among those treated with conventional diabetes therapy. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; DCCT/EDIC ClinicalTrials.gov numbers, NCT00360815 and NCT00360893.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Insulin alone was used to lower blood glucose in the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) study of type 1 diabetes, while a variety of agents were used in clinical trials of type 2 diabetes, supporting the conclusion that lowering blood glucose itself helps prevent CKD and its progression.”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [53]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In both T1D or T2D, lower achieved levels of HbA1c < 7% ( < 53 mmol/mol) versus 8% -9% (64 -75 mmol/mol) reduce risk of overall microvascular complications, including nephropathy and retinopathy, and macrovascular complications in some RCTs. 189 -193”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [191]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In RCTs, targeting lower HbA1c values using glucose-lowering medications has been proven to reduce risks of microvascular diabetes complications (i.e., kidney disease, retinopathy, neuropathy) and, in some studies, also macrovascular diabetes complications (i.e., cardiovascular events).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [191]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intensive lowering of blood glucose with the goal of achieving near-normoglycemia has been shown in large, randomized studies to delay the onset and progression of albuminuria and reduce eGFR in people with type 1 diabetes (54,55) and type 2 diabetes (1,56,57).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [55]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Intensive lowering of blood glucose with the goal of achieving near-normoglycemia has been shown in large, randomized studies to delay the onset and progression of albuminuria and reduce eGFR in people with type 1 diabetes (52,53) and type 2 diabetes (1,(54)(55)(56)(57)(58)(59).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [53]
The cited source says what the claim attributes to it.
In the citing paper
“However, the bene fi ts of more-stringent glycemic control (i.e., lower HbA1c targets) compared with less-stringent glycemic control (i.e., higher HbA1c targets) manifest over many years of treatment. 191,248,249”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [191]
The cited source says what the claim attributes to it.
In the citing paper
“In randomized clinical trials, it has taken a number of years for bene fi ts of intensive glycemic control to manifest as improved clinical outcomes. 190,191,234,245,246,248,256”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [191]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Self-citationA Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Self-citationBrenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Self-citationA Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,957
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
Cited by
Sorted by citations
Items 201–300 of 568
Baker, N. L., Hunt, K. J., Stevens, D. R., Járai, G., Rosen, G., Klein, R. L., Virella, G., & Lopes-Virella, M. F. (2017) · Diabetes Care · doi:10.2337/dc17-0867 · Cited by 35
Fukuda, A., Minakawa, A., Kikuchi, M., Sato, Y., Nagatomo, M., Nakamura, S., Mizoguchi, T., Fukunaga, N., Shibata, H., Naik, A. S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-75320-1 · Cited by 35
Confronting The Urgent Challenge Of Diabetes: An Overview
FRADKIN, J. E. (2012) · Health Affairs · doi:10.1377/hlthaff.2011.1150 · Cited by 34
Tang, M., Berg, A. H., Rhee, E. P., Allegretti, A. S., Nigwekar, S. U., Karumanchi, S. A., Lash, J. P., & Kalim, S. (2022) · Diabetes Care · doi:10.2337/dc22-1399 · Cited by 34
Epigenomics: The Science of No-Longer-Junk DNA. Why Study it in Chronic Kidney Disease?
Ko, Y.-A., & Suszták, K. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2013.05.007 · Cited by 34
Association Between Blood Pressure and Adverse Renal Events in Type 1 Diabetes
Ku, E., McCulloch, C. E., Mauer, M. S., Gitelman, S. E., Grimes, B. A., & Hsu, C. (2016) · Diabetes Care · doi:10.2337/dc16-0857 · Cited by 37
Unwin, D., Unwin, J., Crocombe, D., Delon, C., Guess, N. D., & Wong, C. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000658 · Cited by 34
Chowdhury, N. H., Reaz, M. B. I., Haque, F., Ahmad, S., Ali, S. H. M., Bakar, A. A. A., & Bhuiyan, M. A. S. (2021) · Diagnostics · doi:10.3390/diagnostics11122267 · Cited by 33
Vascular memory: can we broaden the concept of the metabolic memory?
Jermendy, G. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-44 · Cited by 36
Diabetic Kidney Disease and the Cardiorenal Syndrome
Jindal, A., Garcia‐Touza, M., Jindal, N., Whaley‐Connell, A. T., & Sowers, J. R. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.06.002 · Cited by 32
Systems biology building a useful model from multiple markers and profiles
Mayer, P., Mayer, B., & Mayer, G. J. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs489 · Cited by 34
Gabriel, E. E., & Gilbert, P. B. (2013) · Biostatistics · doi:10.1093/biostatistics/kxt055 · Cited by 32
Uric acid and risk of diabetic kidney disease
Mauer, M. S., & Doria, A. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00796-z · Cited by 32
Oduro, P. K., Fang, J., Niu, L., Li, Y., Li, L., Zhao, X., & Wang, Q. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104893 · Cited by 31
Xu, Y., Dong, S., Fu, E. L., Sjölander, A., Grams, M. E., Selvin, E., & Carrero, J. J. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2023.03.007 · Cited by 31
The Epigenome and Its Role in Diabetes
Waki, H., Yamauchi, T., & Kadowaki, T. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0328-x · Cited by 31
Outcomes of pancreas transplantation in older diabetic patients
Montagud‐Marrahí, E., Andújar, A. M., Pané, A., Ramírez-Bajo, M. J., Amor, A. J., Esmatjes, E., Ferrer, J., Musquera, M., Diekmann, F., & Ventura‐Aguiar, P. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000916 · Cited by 30
Guan, G., Xie, J., Dai, Y., & Han, H. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101725 · Cited by 31
Lo, C., Lui, M. L., Ranasinha, S., Teede, H. J., Kerr, P. G., Polkinghorne, K. R., Nathan, D. M., Zheng, H., & Zoungas, S. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.01.020 · Cited by 32
Kim, C., Cleary, P. A., Cowie, C. C., Braffett, B. H., Dunn, R. L., Larkin, M. E., Gatcomb, P., Wessells, H., Nathan, D. M., & Sarma, A. V. (2013) · Diabetes Care · doi:10.2337/dc13-1746 · Cited by 30
Xu, M., Bi, Y., Huang, Y. F., Xie, L., Hao, M., Zhao, Z., Xu, Y., Lu, J., Chen, Y., Sun, Y., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.02.032 · Cited by 29
Renoprotection: focus on TRPV 1, TRPV 4, TRPC 6 and TRPM 2
Markó, L., Mannaa, M., Haschler, T. N., Krämer, S., & Gollasch, M. (2016) · Acta Physiologica · doi:10.1111/apha.12828 · Cited by 29
Catarinella, D., Melzi, R., Mercalli, A., Magistretti, P., Tentori, S., Gremizzi, C., Paloschi, V., COBELLI, F. D., Esposto, G., Costa, S., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00341-3 · Cited by 30
Åkesson, K., Hanberger, L., & Samuelsson, U. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12219 · Cited by 28
Singh, A., Donnino, R. M., WEINTRAUB, H. S., & Schwartzbard, A. Z. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.05.044 · Cited by 28
Yoon, H. J., Lee, Y., Kim, S. R., Rim, T. H., Lee, E. Y., Kang, E. S., Soo, B., Lee, H. C., & Lee, B. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0219-y · Cited by 28
CTLA4-Ig in B7-1-positive diabetic and non-diabetic kidney disease
Bassi, R., Fornoni, A., Doria, A., & Fiorina, P. (2015) · Diabetologia · doi:10.1007/s00125-015-3766-6 · Cited by 27
Metabolic memory and diabetic nephropathy: Beneficial effects of natural epigenetic modifiers
Kushwaha, K., Sharma, S., & Gupta, J. (2020) · Biochimie · doi:10.1016/j.biochi.2020.01.007 · Cited by 32
Kähler, P., Grevstad, B., Almdal, T., Gluud, C. N., Wetterslev, J., Vaag, A. A., & Hemmingsen, B. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-004806 · Cited by 26
Evaluation of Serum Glucose and Kidney Disease Progression Among Patients With Diabetes
Jung, H. H. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.27387 · Cited by 29
Clinical Manifestations and Natural History of Diabetic Kidney Disease
Ritz, E. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.10.008 · Cited by 28
Assessing the value of the Ambulatory Glucose Profile in clinical practice
Matthaei, S. (2014) · The British Journal of Diabetes · doi:10.15277/bjdvd.2014.045 · Cited by 27
Nakamura, T., Fujikura, J., Anazawa, T., Ito, R., Ogura, M., Okajima, H., Üemoto, S., & Inagaki, N. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13128 · Cited by 27
D’Apolito, M., Colia, A. L., Manca, E., Pettoello‐Mantovani, M., Sacco, M. C., Maffione, A. B., Brownlee, M., & Giardino, I. (2018) · Toxins · doi:10.3390/toxins10100410 · Cited by 26
Epigenetic memory contributing to the pathogenesis of AKI-to-CKD transition
Tanemoto, F., Nangaku, M., & Mimura, I. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1003227 · Cited by 27
Li, H., Zha, X., Zhu, Y. M., Liu, M., Guo, R. C., & Wen, Y. (2016) · Medicine · doi:10.1097/md.0000000000003456 · Cited by 25
Diabetic Kidney Disease: From Pathogenesis to Novel Treatment Possibilities
Aboolian, A., Urner, S., Roden, M., Jha, J. C., & Jandeleit-Dahm, K. A. M. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2021_576 · Cited by 25
Lee, C.-L., Li, T., Lin, S., Wang, J., Lee, I., Tseng, L., Song, Y.-M., Tsai, S., & Sheu, W. H. (2013) · American Journal of Nephrology · doi:10.1159/000351803 · Cited by 26
Khan, U., Garg, A. X., Parikh, C. R., & Coca, S. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071784 · Cited by 25
Life after pancreas transplantation
Dunn, T. B. (2013) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000045 · Cited by 26
Preservation of renal function in chronic diabetes by enhancing glomerular glucose metabolism
Qi, W., Li, Q., Gordin, D., & King, G. L. (2018) · Journal of Molecular Medicine · doi:10.1007/s00109-018-1630-0 · Cited by 26
Deep Multi-Output Forecasting: Learning to Accurately Predict Blood Glucose Trajectories
Fox, I., Ang, L. P., Jaiswal, M., Pop‐Busui, R., & Wiens, J. (2018) · PubMed · doi:10.48550/arxiv.1806.05357 · Cited by 24
Yu, G., Zhang, M., Gao, L., Zhou, Y., Qiao, L., Yin, J., Wang, Y., Zhou, J., & Ye, H. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.004 · Cited by 24
Adeva‐Andany, M. M., Fernández‐Fernández, C., Funcasta-Calderón, R., Ameneiros-Rodríguez, E., Adeva-Contreras, L., & Castro-Quintela, E. (2021) · Current Diabetes Reviews · doi:10.2174/1573399818666211117122604 · Cited by 25
Glucose control in diabetes: which target level to aim for?
Laakso, M., & Cederberg, H. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02528.x · Cited by 25
Perco, P., Pena, M. J., Heerspink, H. J. L., & Mayer, G. J. (2018) · Kidney International Reports · doi:10.1016/j.ekir.2018.12.001 · Cited by 25
Zheng, X., Soroush, F., Long, J., Hall, E. T., Adishesha, P. K., Bhattacharya, S., Kiani, M. F., & Bhalla, V. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185250 · Cited by 25
Hughes, E. P., Wang, X. X., Sabol, L., Barton, K., Hegde, S., Myakala, K., Krawczyk, E., Rosenberg, A. Z., & Levi, M. (2025) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00110.2025 · Cited by 27
Orchard, T. J., Backlund, J. C., Costacou, T., Cleary, P. A., Lopes-Virella, M. F., Levy, A. P., & Lachin, J. M. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.07.014 · Cited by 23
Wei, X., Lu, Z., Li, L., Zhang, H., Sun, F., Ma, H., Wang, L., Hu, Y., Yan, Z., Zheng, H., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108207 · Cited by 23
Nephropathy in Youth and Young Adults with Type 2 Diabetes
Solis‐Herrera, C., Triplitt, C. L., & Lynch, J. L. (2014) · Current Diabetes Reports · doi:10.1007/s11892-013-0456-y · Cited by 25
Bjornstad, P., Pyle, L. L., Kinney, G. L., Rewers, M., Johnson, R. J., Maahs, D. M., & Snell‐Bergeon, J. K. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.06.012 · Cited by 22
Rodríguez-Pérez, M. D., López-Villodres, J. A., Arrebola, M. M., Aurioles, E. M., Fernández‐Prior, Á., Oria, A. B., Ríos, M. C., Cruz, J. P. D. L., & Correa, J. A. G. (2021) · Antioxidants · doi:10.3390/antiox10111783 · Cited by 24
Kidney Considerations in Pediatric Obesity
Sawyer, A., Zeitler, E. M., Trachtman, H., & Bjornstad, P. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00522-3 · Cited by 23
A practical method to measure GFR in people with type 1 diabetes
Maahs, D. M., Bushman, L. R., Kerr, B. J., Ellis, S. L., Pyle, L. L., McFann, K., Bouffard, A., Bishop, F. K., Nguyen, N. Q., & Anderson, P. L. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.06.001 · Cited by 22
Comparing and combining biomarkers as principal surrogates for time-to-event clinical endpoints
Gabriel, E. E., Sachs, M. C., & Gilbert, P. B. (2014) · Statistics in Medicine · doi:10.1002/sim.6349 · Cited by 22
Leu, J., Lin, C.-Y., Jian, J., Shih, C.-Y., & Liang, Y. (2013) · Anais da Academia Brasileira de Ciências · doi:10.1590/s0001-37652013005000023 · Cited by 23
Teramo, K. A., & Piñeiro-Ramos, J. D. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.03.012 · Cited by 22
The Pillars for Renal Disease Treatment in Patients with Type 2 Diabetes
Kearney, J., & Gnudi, L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051343 · Cited by 22
Shah, H., McGill, J. B., Hirsch, I. B., Wu, C.-Y., Gałecki, A. T., de Boer, I. H., Mauer, M. S., & Doria, A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae044 · Cited by 20
Comanagement of Diabetic Kidney Disease by the Primary Care Provider and Nephrologist
Bowman, B. T., Kleiner, A., & Bolton, W. K. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.10.012 · Cited by 21
Why do some patients with type 1 diabetes live so long?
Distiller, L. A. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i3.282 · Cited by 21
Yao, Q., Zhang, M., Jiang, R., Wu, Q., Xu, X., Chen, H., & Yang, T. (2016) · Cellular Immunology · doi:10.1016/j.cellimm.2016.09.010 · Cited by 21
Limkunakul, C., de Boer, I. H., Kestenbaum, B. R., Himmelfarb, J., Ikizler, T. A., & Robinson‐Cohen, C. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.12.010 · Cited by 21
Preserving Residual Renal Function in Dialysis: What We Know
Patel, N., & Hu, S. L. (2014) · Seminars in Dialysis · doi:10.1111/sdi.12302 · Cited by 21
It's Time to Move from the A1c to Better Metrics for Diabetes Control
Kowalski, A. J., & Dutta, S. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0060 · Cited by 21
Braffett, B. H., Bebu, I., Lorenzi, G. M., Martin, C. L., Perkins, B. A., Gubitosi‐Klug, R., & Nathan, D. M. (2025) · Diabetes Care · doi:10.2337/dc24-2885 · Cited by 23
Joo, Y. S., Kim, H. W., Nam, K. H., Lee, J. Y., Chang, T. I., Park, J. T., Yoo, T., Lee, J., Kim, S. W., Oh, Y. K., et al. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.17542 · Cited by 20
Association of Hypoglycemia With Incident Chronic Kidney Disease in Patients With Type 2 Diabetes
Shih, C.-J., Wu, Y.-L., Lo, Y., Kuo, S., Tarng, D., Lin, C., Ou, S., & Chen, Y. (2015) · Medicine · doi:10.1097/md.0000000000000771 · Cited by 20
Closing the gap between evidence and practice in chronic kidney disease
Jardine, M., Kasiske, B. L., Adu, D., Alrukhaimi, M. N., Ashuntantang, G., Basnet, S., Chailimpamontree, W., Craig, J. C., O'Donoghue, D. J., Perkovic, V., et al. (2017) · Kidney International Supplements · doi:10.1016/j.kisu.2017.07.006 · Cited by 21
Khan, M. S., Jeon, Y., Lee, C., Yang, J. M., & Kim, S. G. (2025) · Innovations in Acupuncture and Medicine · doi:10.1186/s44424-025-00005-3 · Cited by 21
Diabetes mellitus type 1 in adults
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Шамхалова, М. Ш., Nikonova, T. V., Sukhareva, O. Y., Пекарева, Е. В., Ibragimova, L. I., Mikhina, M. S., Galstyan, G. R., et al. (2020) · Diabetes Mellitus · doi:10.14341/dm12505 · Cited by 19
Differential Gene Expression in Diabetic Nephropathy in Individuals With Type 1 Diabetes
Caramori, M. L., Kim, Y., Goldfine, A. B., Moore, J. H., Rich, S. S., Mychaleckyj, J. C., Kirkpatrick, D. T., Nickerson, H. D., Królewski, A. S., & Mauer, M. S. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4465 · Cited by 19
August, P., Hardison, R. M., Hage, F. G., Marroquin, O. C., McGill, J. B., Rosenberg, Y., Steffes, M. W., Wall, B. M., & Molitch, M. E. (2013) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12281211 · Cited by 19
Mundinger, T. O., & Taborsky, G. J. (2016) · Diabetologia · doi:10.1007/s00125-016-4026-0 · Cited by 19
Bjerre‐Christensen, T., Winther, S. A., Tofte, N., Theilade, S., Ahluwalia, T. S., Lajer, M., Hansen, T. W., Rossing, P. R., & Hansen, C. S. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002289 · Cited by 20
Eun, M., Kim, D., Shin, S.-I., Yang, H. O., Kim, K.-D., Choi, S. Y., Park, S., Kim, D. K., Jeong, C. W., Moon, K. C., et al. (2023) · Kidney International · doi:10.1016/j.kint.2023.09.030 · Cited by 19
Otani, T., Yokoyama, H., Ohashi, Y., & Uchigata, Y. (2016) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2015-000177 · Cited by 18
Impact of intentional weight loss on diabetic kidney disease
Holland, J. A., Martin, W. P., Docherty, N. G., & le Roux, C. W. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13813 · Cited by 19
Tanamas, S. K., Saulnier, P., Fufaa, G. D., Wheelock, K. M., Weil, E. J., Hanson, R. L., Knowler, W. C., Bennett, P. H., & Nelson, R. G. (2016) · Diabetes Care · doi:10.2337/dc16-0795 · Cited by 18
Attenuated kidney oxidative metabolism in young adults with type 1 diabetes
Choi, Y. J., Richard, G. M., Zhang, G., Hodgin, J. B., Demeke, D., Yang, Y., Schaub, J. A., Tamayo, I. M., Gurung, B. K., Naik, A. S., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci183984 · Cited by 18
Diabetic Kidney Disease Prevention Care Model Development
ElSayed, N. A., Bannuru, R. R., Bakris, G. L., Bardsley, J. K., de Boer, I. H., Gabbay, R. A., Gockerman, J. P., McCoy, R. G., McCracken, E., Neumiller, J. J., et al. (2023) · Clinical Diabetes · doi:10.2337/cd23-0063 · Cited by 22
Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes and CKD
Sridhar, V. S., Odutayo, A., Garg, S. V., Danne, T., Doria, A., Mauer, M. S., Davies, M. J., Banks, P. L., Girard, M., & Cherney, D. Z. I. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000540 · Cited by 17
Successes and Disappointments with Clinical Islet Transplantation
Cravedi, P., van der Meer, I. M., Cattaneo, S. G. D. A., Ruggenenti, P. L., & Remuzzi, G. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-90-481-3271-3_33 · Cited by 17
Current therapeutic approaches in the management of hyperglycemia in chronic renal disease
Garla, V. V., Yanes-Cardozo, L. L., & Lien, L. F. (2017) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-017-9416-1 · Cited by 17
Diabetic Kidney Disease: A Determinant of Cardiovascular Risk in Type 1 Diabetes
de Boer, I. H., & Bakris, G. L. (2018) · Diabetes Care · doi:10.2337/dci17-0053 · Cited by 17
Cytosine Methylation Studies in Patients with Diabetic Kidney Disease
Arányi, T., & Suszták, K. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1214-6 · Cited by 17
Hu, W., Hao, H., Yu, W., Wu, X., & Zhou, H. (2015) · BMC Endocrine Disorders · doi:10.1186/s12902-015-0043-0 · Cited by 18
Rodríguez-Pérez, M. D., Santiago-Corral, L., Ortega-Hombrados, L., Verdugo, C., Arrebola, M. M., Aurioles, E. M., Fernández‐Prior, Á., Oria, A. B., Cruz, J. P. D. L., & Correa, J. A. G. (2023) · Nutrients · doi:10.3390/nu15020377 · Cited by 16
Established and Emerging Strategies in the Treatment of Chronic Kidney Disease
Pena-Polanco, J. E., & Fried, L. F. (2016) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2016.05.009 · Cited by 16
Dart, A. B., Wicklow, B. A., Blydt‐Hansen, T. D., Sellers, E. A. C., Malik, S., Chateau, D. G., Sharma, A., & McGavock, J. (2019) · Canadian Journal of Kidney Health and Disease · doi:10.1177/2054358119838836 · Cited by 15
Zhu, S., Hou, S., Lu, Y., Wei, S., Cui, Z., Dong, T., Feng, H., & Wan, Q. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.638477 · Cited by 16
FRADKIN, J. E., Cowie, C. C., Hanlon, M. C., & Rodgers, G. P. (2013) · Diabetes · doi:10.2337/db13-1108 · Cited by 16
Epigenetic Risk Profile of Diabetic Kidney Disease in High-Risk Populations
Xu, L., Natarajan, R. D., & Chen, Z. B. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1129-2 · Cited by 16
Diabetic Nephropathy and Diabetic Kidney Disease
Suneja, M. (2021) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2021.115029 · Cited by 17
Shi, C., Wan, Y., He, A., Wu, X., Shen, X., Zhu, X., Yang, J., & Zhou, Y. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02094-z · Cited by 14
Wang, X., Ren, L., Huang, Y., Feng, Z., Zhang, G., & Dai, H. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117448 · Cited by 15
Diabetes Complications in Childhood Diabetes: New Biomarkers and Technologies
Bjornstad, P., & Maahs, D. M. (2015) · Current Pediatrics Reports · doi:10.1007/s40124-015-0081-0 · Cited by 15
Cantarovich, D., & Perrone, V. (2012) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2012.07.005 · Cited by 15
Update on Blood Pressure Control and Renal Outcomes in Diabetes Mellitus
Joven, M. H., & Anderson, R. J. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0613-6 · Cited by 15
Metadata
- Authors
- The DCCT/EDIC Research Group
- Affiliations
- University of Washington (US)
- Corresponding author
- The DCCT/EDIC Research Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-12-22
- Volume
- 365
- Issue
- 25
- Pages
- 2366-2376
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3270008
- OpenAlex
- W2141495158
- Cited by
- 568
- References
- 28
- Citations by year
- 2026: 4 · 2025: 24 · 2024: 20 · 2023: 34 · 2022: 29 · 2021: 32 · 2020: 40 · 2019: 27 · 2018: 35 · 2017: 35 · 2016: 45 · 2015: 54 · 2014: 58 · 2013: 65 · 2012: 61
- FWCI
- 46.28
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Funders
- Abbott Laboratories
- Eli Lilly and Company
- Sanofi
- Northwestern University
- University of Washington
- Novo Nordisk
- Genentech
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK087726, RC4DK090766, R01DK088762)
- National Center for Research Resources
- Division of Diabetes, Endocrinology, and Metabolic Diseases
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 1 diabetes, intensive diabetes therapy, glomerular filtration rate, diabetic nephropathy, end-stage renal disease, glycemic control, HbA1c, albuminuria, chronic kidney disease
- MeSH terms
- Adult, Creatinine, Diabetes Mellitus, Type 1, Diabetic Nephropathies, Female, Follow-Up Studies, Glomerular Filtration Rate, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Kidney Failure, Chronic, Male, Middle Aged
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
